Lonza Group Ltd Stock News

Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt rat

Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript

Here at the Lab, post Capital Market Day, we are in a show-me-story scenario. Moderna contract termination is a positive short-term catalyst; however, it is an adverse concern over the biotech sector'

Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&

Lonza Group AG (OTCPK:LZAGY) Q2 2023 Earnings Conference Call July 21, 2023 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosse

Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's cap

Lonza Group AG (OTCPK:LZAGY) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Matthew Weston

Lonza Group AG (OTCPK:LZAGY) Q4 2022 Earnings Conference Call January 25, 2023 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vo

No disclosure in Q3, but positive news ahead. Capacity constraint will positively impact Lonza's earnings.

Lonza Group AG (OTCPK:LZAGY) Q2 2022 Earnings Conference Call July 22, 2022 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Daniel Buchta

Lonza is the largest pure-play CDMO in the world. While pharmaceuticals and biotechs need to spend on risky R&D, Lonza just works on large-scale manufacturing.

SAN FRANCISCO , March 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Animal Feed Additives - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 17; Released: February 2022 Executive Pool: 8171 Companies: 272 - Players covered include ADDCON GmbH; Adisseo France SAS; Ajinomoto Co., Inc.; Alltech Inc.; Archer Daniels Midland Company; BASF SE; Cargill, Inc.; Chr. Hansen A/S; CJ CheilJedang Corp.; DelaconBiotechnik GmbH; DSM Nutritional Products; Eastman Chemical Company; Elanco Animal Health; Evonik Industries AG; Kemin Industries, Inc.; Lonza Group Ltd.; METEX NØØVISTAGO; Novozymes A/S; Novus International, Inc.; Nutreco N.V.; Pancosma SA; Phibro Animal Health Corporation; Provimi Holding B.V.; The Mosaic Company; Zoetis, Inc. and Others.

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the global 3D Cell Culture Market finds that increasing incidence of chronic diseases is expediting market growth. Primarily driven by increasing focus on developing alternatives to animal testing, the total global 3D Cell Culture Market is estimated to reach USD 2,051.5 Million by 2028 . The Market stood at a revenue of USD 905.8 Million in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 15.1%. Furthermore, the growing focus on personalized medicine is also anticipated to augment the growth of the global 3D Cell Culture Market, states Vantage Market Research, in a report, titled " 3D Cell Culture Market by Technology (Scaffold based, Scaffold free, 3D Bioreactors), by Application (Cancer, Tissue engineering & Immunohistochemistry, Drug development, Stem cell research), by End Use (Biotechnology and pharmaceutical industries, Research laboratories and institutes, Hospitals and diagnostic centers, Others), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Lonza is a Swiss company in the pharmaceutical ingredients sector. The stock has historically always been expensive and isn't cheap now.